Explore
Validate
Learn
Western blot
Immunocytochemistry
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [121]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA001906 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA001906, RRID:AB_1078249
- Product name
- Anti-ATRX
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human ATRX, Gene description: alpha thalassemia/mental retardation syndrome X-linked, Alternative Gene Names: JMS, RAD54, XH2, XNP, Validated applications: WB, IHC, ICC, Uniprot ID: P46100, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.2 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies
Enrichment of oligodendrocyte precursor phenotypes in subsets of low-grade glioneuronal tumours.
Algorithmic approach utilizing histology and immunohistochemistry for the current classification of diffuse glioma
Case Series: ATRX Variants in Four Patients with Metastatic Pheochromocytoma
A patient-derived cell model for malignant transformation in IDH-mutant glioma
NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma
Differential Expression of SRY-Related HMG-Box Transcription Factor 2, Oligodendrocyte Lineage Transcription Factor 2, and Zinc Finger E-Box Binding Homeobox 1 in Serum-Derived Extracellular Vesicles: Implications for Mithramycin Sensitivity and Targeted Therapy in High-Grade Glioma
P53-negative status and gross total resection as predictive factors for autologous tumor vaccine treatment in newly diagnosed glioblastoma patients
Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas
Clinicopathologic features of gastric glomus tumor: A report of 15 cases and literature review
The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma
Long-term organoid culture of a small intestinal neuroendocrine tumor
Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma
Longitudinal DNA methylation analysis of adult-type IDH-mutant gliomas
ATRX Loss in the Development and Prognosis of Conjunctival Melanoma.
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
Germline MUTYH mutations and high‐grade gliomas: Novel evidence for a potential association
ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats
Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors
The chromatin remodeling protein ATRX positively regulates IRF3-dependent type I interferon production and interferon-induced gene expression
Clinicopathological correlation of glioma patients with respect to immunohistochemistry markers: A prospective study of 115 patients in a Tertiary Care Hospital in North India
Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors.
ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and review of the literature.
Immunohistochemical analyses of the expression profiles of INSM1, ATRX, DAXX and DLL3 in solid papillary carcinomas of the breast.
Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study
Proteome-wide mapping of short-lived proteins in human cells
Low Protein Expression of both ATRX and ZNRF3 as Novel Negative Prognostic Markers of Adult Adrenocortical Carcinoma
Molecular classification and stratification of adult diffuse gliomas: A tertiary care center study
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome
Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma
Human TERT Promoter Mutations in Atypical and Anaplastic Meningiomas
Case Report: Malignant Primary Sellar Paraganglioma With Unusual Genetic and Imaging Features.
A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution
Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.
Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma
Congenital tumors of the central nervous system: an institutional review of 64 cases with emphasis on tumors with unique histologic and molecular characteristics
Generation of Glioblastoma Patient-Derived Intracranial Xenografts for Preclinical Studies
TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors
Reversal of Epigenetic Silencing Allows Robust HIV-1 Replication in the Absence of Integrase Function
Transformation Foci in IDH1-mutated Gliomas Show STAT3 Phosphorylation and Downregulate the Metabolic Enzyme ETNPPL, a Negative Regulator of Glioma Growth
Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Telomere length alterations and ATRX/DAXX loss in pituitary adenomas.
Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells
Recurrent Glioma With Lineage Conversion From Oligodendroglioma to Astrocytoma in Two Cases
ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation
Pituitary Adenoma in Pediatric and Adolescent Populations
ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures
Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways
IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations
Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases
Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas
Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
Telomere alterations in neurofibromatosis type 1-associated solid tumors.
Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency
DNA Methylation Profiling Reveals Prognostically Significant Groups in Pediatric Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry
Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
Hypermethylation of Secreted Frizzled Related Protein 1 gene promoter in different astrocytoma grades
Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach
Inhibition of GPR158 by microRNA-449a suppresses neural lineage of glioma stem/progenitor cells and correlates with higher glioma grades
Granular cell astrocytoma: an aggressive IDH‐wildtype diffuse glioma with molecular genetic features of primary glioblastoma
A unique telomere DNA expansion phenotype in human retinal rod photoreceptors associated with aging and disease
Creutzfeldt astrocytes may be seen in IDH‐wildtype glioblastoma and retain expression of DNA repair and chromatin binding proteins
The molecular landscape of glioma in patients with Neurofibromatosis 1
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody
Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers
Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas
ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
Significance of TERT and ATRX mutations in glioma
Comparison among conventional and advanced MRI, 18F-FDG PET/CT, phenotype and genotype in glioblastoma
DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors
Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome
PARP1expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma
Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss
IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.
The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
CASP9 germline mutation in a family with multiple brain tumors
Bithalamic gliomas may be molecularly distinct from their unilateral high‐grade counterparts
Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival
Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors
P03.10 Combined immunohistochemistry for IDH1R132H, p53 and ATRX improves the molecular classification of diffuse gliomas in adults
Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT
Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors
Microscopy with ultraviolet surface excitation for rapid slide-free histology
Expression and prognostic value of JAM-A in gliomas.
Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study
Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic
IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation
TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes
Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition
Genotyping low-grade gliomas among Hispanics
Adult Diffuse Astrocytoma in the Medulla Oblongata: Molecular Biological Analyses Including H3F3A Mutation of Histone H3.3
Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma‐Tailored Gene Panel
Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12
ATRX binds to atypical chromatin domains at the 3′ exons of zinc finger genes to preserve H3K9me3 enrichment
CDKN2ALoss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) Astrocytomas
ATRX represses alternative lengthening of telomeres
Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas
Diffuse Midline Gliomas with Histone H3‐K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations
Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma
TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast
Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas
Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas
Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells
The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas
Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors
Molecular and Morphologic Correlates of the Alternative Lengthening of Telomeres Phenotype in High‐Grade Astrocytomas
Altered Telomeres in Tumors with ATRX and DAXX Mutations
April-Monn S, Kirchner P, Detjen K, Bräutigam K, Trippel M, Grob T, Statzer C, Maire R, Kollàr A, Chouchane A, Kunze C, Horst D, Sadowski M, Schrader J, Marinoni I, Wiedenmann B, Perren A
npj Precision Oncology 2024;8(1)
npj Precision Oncology 2024;8(1)
Enrichment of oligodendrocyte precursor phenotypes in subsets of low-grade glioneuronal tumours.
Duan Z, Feng J, Guan Y, Li S, Wu B, Shao Y, Ma Z, Hu Z, Xiang L, Zhu M, Fan X, Qi X
Brain communications 2024;6(3):fcae156
Brain communications 2024;6(3):fcae156
Algorithmic approach utilizing histology and immunohistochemistry for the current classification of diffuse glioma
Panambur C
International Journal of Clinical and Experimental Pathology 2024;17(1):13-21
International Journal of Clinical and Experimental Pathology 2024;17(1):13-21
Case Series: ATRX Variants in Four Patients with Metastatic Pheochromocytoma
Cortez B, Kuo M, Jha A, Patel M, Carrasquillo J, Prodanov T, Charles K, Talvacchio S, Derkyi A, Lin F, Taïeb D, Del Rivero J, Pacak K
Frontiers in Endocrinology 2024;15
Frontiers in Endocrinology 2024;15
A patient-derived cell model for malignant transformation in IDH-mutant glioma
Kim O, Sergi Z, Yu G, Yamamoto K, Quezado M, Abdullaev Z, Crooks D, Kishimoto S, Li Q, Lu P, Blackman B, Andresson T, Wu X, Tran B, Wei J, Zhang W, Zhang M, Song H, Khan J, Krishna M, Brender J, Wu J
Acta Neuropathologica Communications 2024;12(1)
Acta Neuropathologica Communications 2024;12(1)
NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
Kim EE, Park CK, Kim SK, Phi JH, Paek SH, Choi JY, Kang HJ, Lee JH, Won JK, Yun H, Park SH
Acta neuropathologica communications 2024 Jul 16;12(1):118
Acta neuropathologica communications 2024 Jul 16;12(1):118
Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma
Takei J, Kamata Y, Tanaka T, Fukasawa N, Gomisawa K, Satake M, Mori R, Yamamoto Y, Suzuki T, Oda A, Murahashi M, Fukuda T, Shimoda M, Murayama Y, Akasaki Y
Cancer Immunology, Immunotherapy 2023;72(10):3175-3189
Cancer Immunology, Immunotherapy 2023;72(10):3175-3189
Differential Expression of SRY-Related HMG-Box Transcription Factor 2, Oligodendrocyte Lineage Transcription Factor 2, and Zinc Finger E-Box Binding Homeobox 1 in Serum-Derived Extracellular Vesicles: Implications for Mithramycin Sensitivity and Targeted Therapy in High-Grade Glioma
Patnam S, Majumder B, Joshi P, Singh A, Nagalla B, Kumar D, Biswas M, Ranjan A, Majumder P, Rengan A, Kamath A, Ray A, Manda S
ACS Pharmacology & Translational Science 2023;7(1):137-149
ACS Pharmacology & Translational Science 2023;7(1):137-149
P53-negative status and gross total resection as predictive factors for autologous tumor vaccine treatment in newly diagnosed glioblastoma patients
Yamada E, Ishikawa E, Miyazaki T, Miki S, Sugii N, Kohzuki H, Tsurubuchi T, Sakamoto N, Watanabe S, Matsuda M
Neuro-Oncology Advances 2023;5(1)
Neuro-Oncology Advances 2023;5(1)
Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas
Bredel M, Espinosa L, Kim H, Scholtens D, McElroy J, Rajbhandari R, Meng W, Kollmeyer T, Malta T, Quezada M, Harsh G, Lobo-Jarne T, Solé L, Merati A, Nagaraja S, Nair S, White J, Thudi N, Fleming J, Webb A, Natsume A, Ogawa S, Weber R, Bertran J, Haque S, Hentschel B, Miller C, Furnari F, Chan T, Grosu A, Weller M, Barnholtz-Sloan J, Monje M, Noushmehr H, Jenkins R, Rogers C, MacDonald D, Pugh S, Chakravarti A
Cell Reports Medicine 2023;4(6):101082
Cell Reports Medicine 2023;4(6):101082
Clinicopathologic features of gastric glomus tumor: A report of 15 cases and literature review
Deng M, Luo R, Huang J, Luo Y, Song Q, Liang H, Xu C, Yuan W, Hou Y
Pathology and Oncology Research 2023;28
Pathology and Oncology Research 2023;28
The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma
Li X, Moreira D, Bag A, Qaddoumi I, Acharya S, Chiang J
Neuro-Oncology 2023;25(4):750-760
Neuro-Oncology 2023;25(4):750-760
Long-term organoid culture of a small intestinal neuroendocrine tumor
D’Agosto S, Fiorini E, Pezzini F, Delfino P, Simbolo M, Vicentini C, Andreani S, Capelli P, Rusev B, Lawlor R, Bassi C, Landoni L, Pea A, Luchini C, Scarpa A, Corbo V
Frontiers in Endocrinology 2023;14
Frontiers in Endocrinology 2023;14
Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas
Bedics G, Szőke P, Bátai B, Nagy T, Papp G, Kránitz N, Rajnai H, Reiniger L, Bödör C, Scheich B
Scientific Reports 2023;13(1)
Scientific Reports 2023;13(1)
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma
Cole K, Ijaz H, Surrey L, Santi M, Liu X, Minard C, Maris J, Voss S, Reid J, Fox E, Weigel B
Cancer 2023;129(14):2245-2255
Cancer 2023;129(14):2245-2255
Longitudinal DNA methylation analysis of adult-type IDH-mutant gliomas
Ferreyra Vega S, Olsson Bontell T, Kling T, Jakola A, Carén H
Acta Neuropathologica Communications 2023;11(1)
Acta Neuropathologica Communications 2023;11(1)
ATRX Loss in the Development and Prognosis of Conjunctival Melanoma.
van Ipenburg JA, van den Bosch QCC, Paridaens D, Dubbink HJ, Kiliç E, Naus N, Verdijk RM, Rotterdam Ocular Melanoma Study Group
International journal of molecular sciences 2023 Aug 20;24(16)
International journal of molecular sciences 2023 Aug 20;24(16)
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
Hackeng W, Brosens L, Kim J, O'Sullivan R, Sung Y, Liu T, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink F, Heidsma C, Valk G, Vriens M, Nieveen van Dijkum E, Offerhaus G, Dreijerink K, Zeh H, Zureikat A, Hogg M, Lee K, Geller D, Marsh J, Paniccia A, Ongchin M, Pingpank J, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella K, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova M, Lawlor R, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong S, Heaphy C, Singhi A
Gut 2022;71(5):961-973
Gut 2022;71(5):961-973
Germline MUTYH mutations and high‐grade gliomas: Novel evidence for a potential association
Bedics G, Kotmayer L, Zajta E, Hegyi L, Brückner E, Rajnai H, Reiniger L, Bödör C, Garami M, Scheich B
Genes, Chromosomes and Cancer 2022;61(10):622-628
Genes, Chromosomes and Cancer 2022;61(10):622-628
ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats
Frank L, Rademacher A, Mücke N, Tirier S, Koeleman E, Knotz C, Schumacher S, Stainczyk S, Westermann F, Fröhling S, Chudasama P, Rippe K
Nucleic Acids Research 2022;50(11):e61-e61
Nucleic Acids Research 2022;50(11):e61-e61
Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors
Momeni Boroujeni A, Kertowidjojo E, Wu X, Soslow R, Chiang S, Da Silva E, Weigelt B, Chui M
Modern Pathology 2022;35(11):1684-1694
Modern Pathology 2022;35(11):1684-1694
The chromatin remodeling protein ATRX positively regulates IRF3-dependent type I interferon production and interferon-induced gene expression
Kalejta R, Stilp A, Scherer M, König P, Fürstberger A, Kestler H, Stamminger T
PLOS Pathogens 2022;18(8):e1010748
PLOS Pathogens 2022;18(8):e1010748
Clinicopathological correlation of glioma patients with respect to immunohistochemistry markers: A prospective study of 115 patients in a Tertiary Care Hospital in North India
Dahuja G, Gupta A, Jindal A, Jain G, Sharma S, Kumar A
Asian Journal of Neurosurgery 2022;16(04):732-737
Asian Journal of Neurosurgery 2022;16(04):732-737
Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors.
Kim H, Lim KY, Park JW, Kang J, Won JK, Lee K, Shim Y, Park CK, Kim SK, Choi SH, Kim TM, Yun H, Park SH
Laboratory investigation; a journal of technical methods and pathology 2022 Feb;102(2):160-171
Laboratory investigation; a journal of technical methods and pathology 2022 Feb;102(2):160-171
ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and review of the literature.
Sumislawski P, Rotermund R, Klose S, Lautenbach A, Wefers AK, Soltwedel C, Mohammadi B, Jacobsen F, Mawrin C, Flitsch J, Saeger W
Endocrine 2022 Apr;76(1):228-236
Endocrine 2022 Apr;76(1):228-236
Immunohistochemical analyses of the expression profiles of INSM1, ATRX, DAXX and DLL3 in solid papillary carcinomas of the breast.
Yanai H, Ishida M, Yoshikawa K, Tsuta K, Sekimoto M, Sugie T
Oncology letters 2022 Apr;23(4):137
Oncology letters 2022 Apr;23(4):137
Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study
Habiba U, Sugino H, Yordanova R, Ise K, Tanei Z, Ishida Y, Tanikawa S, Terasaka S, Sato K, Kamoshima Y, Katoh M, Nagane M, Shibahara J, Tsuda M, Tanaka S
Acta Neuropathologica Communications 2021;9(1)
Acta Neuropathologica Communications 2021;9(1)
Proteome-wide mapping of short-lived proteins in human cells
Li J, Cai Z, Vaites L, Shen N, Mitchell D, Huttlin E, Paulo J, Harry B, Gygi S
Molecular Cell 2021;81(22):4722-4735.e5
Molecular Cell 2021;81(22):4722-4735.e5
Low Protein Expression of both ATRX and ZNRF3 as Novel Negative Prognostic Markers of Adult Adrenocortical Carcinoma
Brondani V, Lacombe A, Mariani B, Montenegro L, Soares I, Bezerra-Neto J, Tanno F, Srougi V, Chambo J, Mendonca B, Almeida M, Zerbini M, Fragoso M
International Journal of Molecular Sciences 2021;22(3):1238
International Journal of Molecular Sciences 2021;22(3):1238
Molecular classification and stratification of adult diffuse gliomas: A tertiary care center study
Anand N, Husain N, Varshney R, Malhotra K, Kaif M
Journal of Carcinogenesis 2021;20(1):20
Journal of Carcinogenesis 2021;20(1):20
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome
Hartlieb S, Sieverling L, Nadler-Holly M, Ziehm M, Toprak U, Herrmann C, Ishaque N, Okonechnikov K, Gartlgruber M, Park Y, Wecht E, Savelyeva L, Henrich K, Rosswog C, Fischer M, Hero B, Jones D, Pfaff E, Witt O, Pfister S, Volckmann R, Koster J, Kiesel K, Rippe K, Taschner-Mandl S, Ambros P, Brors B, Selbach M, Feuerbach L, Westermann F
Nature Communications 2021;12(1)
Nature Communications 2021;12(1)
Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma
He C, Xu K, Zhu X, Dunphy P, Gudenas B, Lin W, Twarog N, Hover L, Kwon C, Kasper L, Zhang J, Li X, Dalton J, Jonchere B, Mercer K, Currier D, Caufield W, Wang Y, Xie J, Broniscer A, Wetmore C, Upadhyaya S, Qaddoumi I, Klimo P, Boop F, Gajjar A, Zhang J, Orr B, Robinson G, Monje M, Freeman III B, Roussel M, Northcott P, Chen T, Rankovic Z, Wu G, Chiang J, Tinkle C, Shelat A, Baker S
Nature Communications 2021;12(1)
Nature Communications 2021;12(1)
Human TERT Promoter Mutations in Atypical and Anaplastic Meningiomas
Mellai M, Porrini Prandini O, Mustaccia A, Fogazzi V, Allesina M, Krengli M, Boldorini R
Diagnostics 2021;11(9):1624
Diagnostics 2021;11(9):1624
Case Report: Malignant Primary Sellar Paraganglioma With Unusual Genetic and Imaging Features.
Stojanoski S, Boldt HB, Kozic D, Patócs A, Korbonits M, Medic-Stojanoska M, Casar-Borota O
Frontiers in oncology 2021;11:739255
Frontiers in oncology 2021;11:739255
A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution
Abedi A, Grunnet K, Christensen I, Michaelsen S, Muhic A, Møller S, Hasselbalch B, Poulsen H, Urup T
Frontiers in Oncology 2021;11
Frontiers in Oncology 2021;11
Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.
Casar-Borota O, Boldt HB, Engström BE, Andersen MS, Baussart B, Bengtsson D, Berinder K, Ekman B, Feldt-Rasmussen U, Höybye C, Jørgensen JOL, Kolnes AJ, Korbonits M, Rasmussen ÅK, Lindsay JR, Loughrey PB, Maiter D, Manojlovic-Gacic E, Pahnke J, Poliani PL, Popovic V, Ragnarsson O, Schalin-Jäntti C, Scheie D, Tóth M, Villa C, Wirenfeldt M, Kunicki J, Burman P
The Journal of clinical endocrinology and metabolism 2021 Mar 25;106(4):1183-1194
The Journal of clinical endocrinology and metabolism 2021 Mar 25;106(4):1183-1194
Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis
ENOMOTO T, AOKI M, HAMASAKI M, ABE H, NONAKA M, INOUE T, NABESHIMA K
Neurologia medico-chirurgica 2020;60(3):136-146
Neurologia medico-chirurgica 2020;60(3):136-146
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma
George S, Lorenzi F, King D, Hartlieb S, Campbell J, Pemberton H, Toprak U, Barker K, Tall J, da Costa B, van den Boogaard M, Dolman M, Molenaar J, Bryant H, Westermann F, Lord C, Chesler L
eBioMedicine 2020;59
eBioMedicine 2020;59
Congenital tumors of the central nervous system: an institutional review of 64 cases with emphasis on tumors with unique histologic and molecular characteristics
Viaene A, Pu C, Perry A, Li M, Luo M, Santi M
Brain Pathology 2020;31(1):45-60
Brain Pathology 2020;31(1):45-60
Generation of Glioblastoma Patient-Derived Intracranial Xenografts for Preclinical Studies
Kerstetter-Fogle A, Harris P, Brady-Kalnay S, Sloan A
International Journal of Molecular Sciences 2020;21(14):5113
International Journal of Molecular Sciences 2020;21(14):5113
TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors
Hernández-Laín A, Meléndez B, Salmon I, Rey J, Lebrun L, Castresana J, Fiaño C, Rodríguez de Lope Á, Gutiérrez-Guamán M, D’Haene N, Sepúlveda J, Mollejo M, Cantero D
Neuro-Oncology Advances 2020;2(1)
Neuro-Oncology Advances 2020;2(1)
Reversal of Epigenetic Silencing Allows Robust HIV-1 Replication in the Absence of Integrase Function
Irwan I, Karnowski H, Bogerd H, Tsai K, Cullen B, Griffin D
mBio 2020;11(3)
mBio 2020;11(3)
Transformation Foci in IDH1-mutated Gliomas Show STAT3 Phosphorylation and Downregulate the Metabolic Enzyme ETNPPL, a Negative Regulator of Glioma Growth
Leventoux N, Augustus M, Azar S, Riquier S, Villemin J, Guelfi S, Falha L, Bauchet L, Gozé C, Ritchie W, Commes T, Duffau H, Rigau V, Hugnot J
Scientific Reports 2020;10(1)
Scientific Reports 2020;10(1)
Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital
Egaña L, Auzmendi-Iriarte J, Andermatten J, Villanua J, Ruiz I, Elua-Pinin A, Aldaz P, Querejeta A, Sarasqueta C, Zubia F, Matheu A, Samprón N
Scientific Reports 2020;10(1)
Scientific Reports 2020;10(1)
Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV, Sørensen MD, Pusch S, Beier D, Bouillon AS, Kristensen BW, Brümmendorf TH, Beier CP, Beier F
Journal of neuro-oncology 2020 Mar;147(1):1-14
Journal of neuro-oncology 2020 Mar;147(1):1-14
Telomere length alterations and ATRX/DAXX loss in pituitary adenomas.
Heaphy CM, Bi WL, Coy S, Davis C, Gallia GL, Santagata S, Rodriguez FJ
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Aug;33(8):1475-1481
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020 Aug;33(8):1475-1481
Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells
Yost K, Clatterbuck Soper S, Walker R, Pineda M, Zhu Y, Ester C, Showman S, Roschke A, Waterfall J, Meltzer P
Scientific Reports 2019;9(1)
Scientific Reports 2019;9(1)
Recurrent Glioma With Lineage Conversion From Oligodendroglioma to Astrocytoma in Two Cases
Kim J, Jang W, Jung T, Jung S, Kim K, Kim H, Kim E, Lee M, Moon K, Lee K
Frontiers in Oncology 2019;9
Frontiers in Oncology 2019;9
ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation
Rodriguez F, Curtis M, Heaphy C, Eberhart C, Wang Z, Nagurney M, Martínez H
Journal of Neuropathology & Experimental Neurology 2019;78(8):703-708
Journal of Neuropathology & Experimental Neurology 2019;78(8):703-708
Pituitary Adenoma in Pediatric and Adolescent Populations
Chen J, Schmidt R, Dahiya S
Journal of Neuropathology & Experimental Neurology 2019;78(7):626-632
Journal of Neuropathology & Experimental Neurology 2019;78(7):626-632
ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures
Qadeer Z, Valle-Garcia D, Hasson D, Sun Z, Cook A, Nguyen C, Soriano A, Ma A, Griffiths L, Zeineldin M, Filipescu D, Jubierre L, Chowdhury A, Deevy O, Chen X, Finkelstein D, Bahrami A, Stewart E, Federico S, Gallego S, Dekio F, Fowkes M, Meni D, Maris J, Weiss W, Roberts S, Cheung N, Jin J, Segura M, Dyer M, Bernstein E
Cancer Cell 2019;36(5):512-527.e9
Cancer Cell 2019;36(5):512-527.e9
Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways
Steele C, Tarabichi M, Oukrif D, Webster A, Ye H, Fittall M, Lombard P, Martincorena I, Tarpey P, Collord G, Haase K, Strauss S, Berisha F, Vaikkinen H, Dhami P, Jansen M, Behjati S, Amary M, Tirabosco R, Feber A, Campbell P, Alexandrov L, Van Loo P, Flanagan A, Pillay N
Cancer Cell 2019;35(3):441-456.e8
Cancer Cell 2019;35(3):441-456.e8
IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations
Yang R, Shi Z, Zhang Z, Chan A, Aibaidula A, Wang W, Kwan J, Poon W, Chen H, Li W, Chung N, Punchhi G, Chu W, Chan I, Liu X, Mao Y, Li K, Ng H
Brain Pathology 2019;30(3):541-553
Brain Pathology 2019;30(3):541-553
Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases
Kwon M, Kang S, Cho H, Lee J, Kim S, Suh Y
Brain Pathology 2019;30(2):235-245
Brain Pathology 2019;30(2):235-245
Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas
Wang L, Li Z, Piao Y, Cai Y, Zhang L, Ge H, Xu W, Lu D
Chinese Medical Journal 2019;132(24):2920-2926
Chinese Medical Journal 2019;132(24):2920-2926
Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
Rodriguez FJ, Brosnan-Cashman JA, Allen SJ, Vizcaino MA, Giannini C, Camelo-Piragua S, Webb M, Matsushita M, Wadhwani N, Tabbarah A, Hamideh D, Jiang L, Chen L, Arvanitis LD, Alnajar HH, Barber JR, Rodríguez-Velasco A, Orr B, Heaphy CM
Brain pathology (Zurich, Switzerland) 2019 Jan;29(1):126-140
Brain pathology (Zurich, Switzerland) 2019 Jan;29(1):126-140
Telomere alterations in neurofibromatosis type 1-associated solid tumors.
Rodriguez FJ, Graham MK, Brosnan-Cashman JA, Barber JR, Davis C, Vizcaino MA, Palsgrove DN, Giannini C, Pekmezci M, Dahiya S, Gokden M, Noë M, Wood LD, Pratilas CA, Morris CD, Belzberg A, Blakeley J, Heaphy CM
Acta neuropathologica communications 2019 Aug 28;7(1):139
Acta neuropathologica communications 2019 Aug 28;7(1):139
Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency
Han M, Napier C, Frölich S, Teber E, Wong T, Noble J, Choi E, Everett R, Cesare A, Reddel R
Journal of Cell Science 2019
Journal of Cell Science 2019
DNA Methylation Profiling Reveals Prognostically Significant Groups in Pediatric Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry
Clay M, Pinto E, Cline C, Tran Q, Lin T, Dyer M, Shi L, Wu H, Pounds S, Zambetti G, Orr B, Ribeiro R
JCO Precision Oncology 2019
JCO Precision Oncology 2019
Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST
Lu H, Eulo V, Apicelli A, Pekmezci M, Tao Y, Luo J, Hirbe A, Dahiya S
Oncotarget 2018;9(33):23018-23028
Oncotarget 2018;9(33):23018-23028
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
Diplas B, He X, Brosnan-Cashman J, Liu H, Chen L, Wang Z, Moure C, Killela P, Loriaux D, Lipp E, Greer P, Yang R, Rizzo A, Rodriguez F, Friedman A, Friedman H, Wang S, He Y, McLendon R, Bigner D, Jiao Y, Waitkus M, Meeker A, Yan H
Nature Communications 2018;9(1)
Nature Communications 2018;9(1)
Hypermethylation of Secreted Frizzled Related Protein 1 gene promoter in different astrocytoma grades
Kafka A, Karin-Kujundžić V, Šerman L, Bukovac A, Njirić N, Jakovčević A, Pećina-Šlaus N
Croatian Medical Journal 2018;59(5):213-223
Croatian Medical Journal 2018;59(5):213-223
Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach
Kim S, Lee Y, Won J, Park C, Choi S, Park S
Journal of Pathology and Translational Medicine 2018;52(1):28-36
Journal of Pathology and Translational Medicine 2018;52(1):28-36
Inhibition of GPR158 by microRNA-449a suppresses neural lineage of glioma stem/progenitor cells and correlates with higher glioma grades
Li N, Zhang Y, Sidlauskas K, Ellis M, Evans I, Frankel P, Lau J, El-Hassan T, Guglielmi L, Broni J, Richard-Loendt A, Brandner S
Oncogene 2018;37(31):4313-4333
Oncogene 2018;37(31):4313-4333
Granular cell astrocytoma: an aggressive IDH‐wildtype diffuse glioma with molecular genetic features of primary glioblastoma
Vizcaino M, Palsgrove D, Yuan M, Giannini C, Cabrera‐Aldana E, Pallavajjala A, Burger P, Rodriguez F
Brain Pathology 2018;29(2):193-204
Brain Pathology 2018;29(2):193-204
A unique telomere DNA expansion phenotype in human retinal rod photoreceptors associated with aging and disease
Bell W, Meeker A, Rizzo A, Rajpara S, Rosenthal I, Flores Bellver M, Aparicio Domingo S, Zhong X, Barber J, Joshu C, Canto‐Soler M, Eberhart C, Heaphy C
Brain Pathology 2018;29(1):45-52
Brain Pathology 2018;29(1):45-52
Creutzfeldt astrocytes may be seen in IDH‐wildtype glioblastoma and retain expression of DNA repair and chromatin binding proteins
Ballester L, Boghani Z, Baskin D, Britz G, Olsen R, Fuller G, Powell S, Cykowski M
Brain Pathology 2018;28(6):1012-1019
Brain Pathology 2018;28(6):1012-1019
The molecular landscape of glioma in patients with Neurofibromatosis 1
D’Angelo F, Ceccarelli M, Tala , Garofano L, Zhang J, Frattini V, Caruso F, Lewis G, Alfaro K, Bauchet L, Berzero G, Cachia D, Cangiano M, Capelle L, de Groot J, DiMeco F, Ducray F, Farah W, Finocchiaro G, Goutagny S, Kamiya-Matsuoka C, Lavarino C, Loiseau H, Lorgis V, Marras C, McCutcheon I, Nam D, Ronchi S, Saletti V, Seizeur R, Slopis J, Suñol M, Vandenbos F, Varlet P, Vidaud D, Watts C, Tabar V, Reuss D, Kim S, Meyronet D, Mokhtari K, Salvador H, Bhat K, Eoli M, Sanson M, Lasorella A, Iavarone A
Nature Medicine 2018;25(1):176-187
Nature Medicine 2018;25(1):176-187
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
Byron S, Tran N, Halperin R, Phillips J, Kuhn J, de Groot J, Colman H, Ligon K, Wen P, Cloughesy T, Mellinghoff I, Butowski N, Taylor J, Clarke J, Chang S, Berger M, Molinaro A, Maggiora G, Peng S, Nasser S, Liang W, Trent J, Berens M, Carpten J, Craig D, Prados M
Clinical Cancer Research 2018;24(2):295-305
Clinical Cancer Research 2018;24(2):295-305
Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody
Masui K, Komori T, Kato Y, Masutomi K, Ichimura K, Ogasawara S, Kaneko M, Oki H, Suzuki H, Nitta M, Maruyama T, Muragaki Y, Kawamata T, Sawada T, Shibata N
BioMed Research International 2018;2018
BioMed Research International 2018;2018
Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers
Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T
Disease Markers 2018;2018
Disease Markers 2018;2018
Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas
Hayes J, Yu Y, Jalbert L, Mazor T, Jones L, Wood M, Walsh K, Bengtsson H, Hong C, Oberndorfer S, Roetzer T, Smirnov I, Clarke J, Aghi M, Chang S, Nelson S, Woehrer A, Phillips J, Solomon D, Costello J
Neuro-Oncology 2018;20(5):632-641
Neuro-Oncology 2018;20(5):632-641
ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
Brosnan-Cashman JA, Yuan M, Graham MK, Rizzo AJ, Myers KM, Davis C, Zhang R, Esopi DM, Raabe EH, Eberhart CG, Heaphy CM, Meeker AK
PloS one 2018;13(9):e0204159
PloS one 2018;13(9):e0204159
Significance of TERT and ATRX mutations in glioma
Liu J, Zhang X, Yan X, Sun M, Fan Y, Huang Y
Oncology Letters 2018
Oncology Letters 2018
Comparison among conventional and advanced MRI, 18F-FDG PET/CT, phenotype and genotype in glioblastoma
Valentini M, Mellai M, Annovazzi L, Melcarne A, Denysenko T, Cassoni P, Casalone C, Maurella C, Grifoni S, Fania P, Cistaro A, Schiffer D
Oncotarget 2017;8(53):91636-91653
Oncotarget 2017;8(53):91636-91653
DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors
Park J, Paik W, Lee K, Ryu J, Lee S, Kim Y
Oncotarget 2017;8(30):49796-49806
Oncotarget 2017;8(30):49796-49806
Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome
Kiviniemi A, Gardberg M, Kivinen K, Posti J, Vuorinen V, Sipilä J, Rahi M, Sankinen M, Minn H
Oncotarget 2017;8(30):49123-49132
Oncotarget 2017;8(30):49123-49132
PARP1expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma
Murnyák B, Kouhsari M, Hershkovitch R, Kálmán B, Marko-Varga G, Klekner Á, Hortobágyi T
Oncotarget 2017;8(28):46348-46362
Oncotarget 2017;8(28):46348-46362
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A, Romano D, Saveanu A, Roche C, Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero J, Garcia S, Ferone D, Florio T, Moutardier V, Poizat F, Barlier A, Gerard C
Oncotarget 2017;8(25):41044-41063
Oncotarget 2017;8(25):41044-41063
Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma
Pratt D, Pittaluga S, Palisoc M, Fetsch P, Xi L, Raffeld M, Gilbert M, Quezado M
Journal of Neuropathology & Experimental Neurology 2017;76(8):697-708
Journal of Neuropathology & Experimental Neurology 2017;76(8):697-708
Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss
Li X, Wei J, Liu Y, Li P, Fan L, Wang Y, Li M, Zhao D, Yu Z, Ye J, Guo Y, Yan Q, Guo S, Wang Z
Scientific Reports 2017;7(1)
Scientific Reports 2017;7(1)
IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.
Cleven AHG, Suijker J, Agrogiannis G, Briaire-de Bruijn IH, Frizzell N, Hoekstra AS, Wijers-Koster PM, Cleton-Jansen AM, Bovée JVMG
Clinical sarcoma research 2017;7:8
Clinical sarcoma research 2017;7:8
The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
Lee Y, Koh J, Kim S, Won J, Park C, Choi S, Park S
Acta Neuropathologica Communications 2017;5(1)
Acta Neuropathologica Communications 2017;5(1)
CASP9 germline mutation in a family with multiple brain tumors
Ronellenfitsch M, Oh J, Satomi K, Sumi K, Harter P, Steinbach J, Felsberg J, Capper D, Voegele C, Durand G, McKay J, Le Calvez‐Kelm F, Schittenhelm J, Klink B, Mittelbronn M, Ohgaki H
Brain Pathology 2017;28(1):94-102
Brain Pathology 2017;28(1):94-102
Bithalamic gliomas may be molecularly distinct from their unilateral high‐grade counterparts
Broniscer A, Hwang S, Chamdine O, Lin T, Pounds S, Onar‐Thomas A, Chi L, Shurtleff S, Allen S, Gajjar A, Northcott P, Orr B
Brain Pathology 2017;28(1):112-120
Brain Pathology 2017;28(1):112-120
Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival
Kim J, Brosnan-Cashman J, An S, Kim S, Song K, Kim M, Kim M, Hwang D, Meeker A, Yu E, Kim S, Hruban R, Heaphy C, Hong S
Clinical Cancer Research 2017;23(6):1598-1606
Clinical Cancer Research 2017;23(6):1598-1606
Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors
Singhi A, Liu T, Roncaioli J, Cao D, Zeh H, Zureikat A, Tsung A, Marsh J, Lee K, Hogg M, Bahary N, Brand R, McGrath K, Slivka A, Cressman K, Fuhrer K, O'Sullivan R
Clinical Cancer Research 2017;23(2):600-609
Clinical Cancer Research 2017;23(2):600-609
P03.10 Combined immunohistochemistry for IDH1R132H, p53 and ATRX improves the molecular classification of diffuse gliomas in adults
Komori T, Nitta M, Maruyama T, Muragaki Y, Kawamata T
Neuro-Oncology 2017;19(suppl_3):iii35-iii35
Neuro-Oncology 2017;19(suppl_3):iii35-iii35
Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT
Pekmezci M, Rice T, Molinaro A, Walsh K, Decker P, Hansen H, Sicotte H, Kollmeyer T, McCoy L, Sarkar G, Perry A, Giannini C, Tihan T, Berger M, Wiemels J, Bracci P, Eckel-Passow J, Lachance D, Clarke J, Taylor J, Luks T, Wiencke J, Jenkins R, Wrensch M
Acta Neuropathologica 2017;133(6):1001-1016
Acta Neuropathologica 2017;133(6):1001-1016
Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors
VandenBussche C, Allison D, Graham M, Charu V, Lennon A, Wolfgang C, Hruban R, Heaphy C
Cancer Cytopathology 2017;125(7):544-551
Cancer Cytopathology 2017;125(7):544-551
Microscopy with ultraviolet surface excitation for rapid slide-free histology
Fereidouni F, Harmany Z, Tian M, Todd A, Kintner J, McPherson J, Borowsky A, Bishop J, Lechpammer M, Demos S, Levenson R
Nature Biomedical Engineering 2017;1(12):957-966
Nature Biomedical Engineering 2017;1(12):957-966
Expression and prognostic value of JAM-A in gliomas.
Rosager AM, Sørensen MD, Dahlrot RH, Boldt HB, Hansen S, Lathia JD, Kristensen BW
Journal of neuro-oncology 2017 Oct;135(1):107-117
Journal of neuro-oncology 2017 Oct;135(1):107-117
Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study
Kim M, Camelo-Piragua S, Schipper M, Tao Y, Normolle D, Junck L, Mammoser A, Betz B, Cao Y, Kim C, Heth J, Sagher O, Lawrence T, Tsien C
International Journal of Radiation Oncology*Biology*Physics 2016;94(2):305-311
International Journal of Radiation Oncology*Biology*Physics 2016;94(2):305-311
Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic
Li Y, Shi Z, Aibaidula A, Chen H, Tang Q, Li K, Chung N, Chan D, Poon W, Mao Y, Wu J, Zhou L, Chan A, Ng H
Oncotarget 2016;7(40):64615-64630
Oncotarget 2016;7(40):64615-64630
IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation
Oktay Y, Ülgen E, Can Ö, Akyerli C, Yüksel Ş, Erdemgil Y, Durası İ, Henegariu O, Nanni E, Selevsek N, Grossmann J, Erson-Omay E, Bai H, Gupta M, Lee W, Turcan Ş, Özpınar A, Huse J, Sav M, Flanagan A, Günel M, Sezerman O, Yakıcıer M, Pamir M, Özduman K
Scientific Reports 2016;6(1)
Scientific Reports 2016;6(1)
TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes
Vinagre J, Nabais J, Pinheiro J, Batista R, Oliveira R, Gonçalves A, Pestana A, Reis M, Mesquita B, Pinto V, Lyra J, Cipriano M, Ferreira M, Lopes J, Sobrinho-Simões M, Soares P
Scientific Reports 2016;6(1)
Scientific Reports 2016;6(1)
Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition
Deeg K, Chung I, Bauer C, Rippe K
Frontiers in Oncology 2016;6
Frontiers in Oncology 2016;6
Genotyping low-grade gliomas among Hispanics
Cardona A, Rojas L, Wills B, Behaine J, Jiménez E, Hakim F, Useche N, Bermúdez S, Arrieta O, Mejía J, Ramón J, Carranza H, Vargas C, Otero J, González D, Rodríguez J, Ortiz L, Cifuentes H, Balaña C
Neuro-Oncology Practice 2016;3(3):164-172
Neuro-Oncology Practice 2016;3(3):164-172
Adult Diffuse Astrocytoma in the Medulla Oblongata: Molecular Biological Analyses Including H3F3A Mutation of Histone H3.3
Uekawa K, Nakamura H, Shinojima N, Takezaki T, Yano S, Kuratsu J
NMC Case Report Journal 2016;3(2):29-33
NMC Case Report Journal 2016;3(2):29-33
Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma‐Tailored Gene Panel
Zacher A, Kaulich K, Stepanow S, Wolter M, Köhrer K, Felsberg J, Malzkorn B, Reifenberger G
Brain Pathology 2016;27(2):146-159
Brain Pathology 2016;27(2):146-159
Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12
Morton C, Mäkinen N, Aavikko M, Heikkinen T, Taipale M, Taipale J, Koivisto-Korander R, Bützow R, Vahteristo P
PLOS Genetics 2016;12(2):e1005850
PLOS Genetics 2016;12(2):e1005850
ATRX binds to atypical chromatin domains at the 3′ exons of zinc finger genes to preserve H3K9me3 enrichment
Valle-García D, Qadeer Z, McHugh D, Ghiraldini F, Chowdhury A, Hasson D, Dyer M, Recillas-Targa F, Bernstein E
Epigenetics 2016;11(6):398-414
Epigenetics 2016;11(6):398-414
CDKN2ALoss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) Astrocytomas
Reis G, Pekmezci M, Hansen H, Rice T, Marshall R, Molinaro A, Phillips J, Vogel H, Wiencke J, Wrensch M, Walsh K, Perry A
Journal of Neuropathology & Experimental Neurology 2015;74(5):442-452
Journal of Neuropathology & Experimental Neurology 2015;74(5):442-452
ATRX represses alternative lengthening of telomeres
Napier C, Huschtscha L, Harvey A, Bower K, Noble J, Hendrickson E, Reddel R
Oncotarget 2015;6(18):16543-16558
Oncotarget 2015;6(18):16543-16558
Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort
Hayashi S, Sasaki H, Kimura T, Abe T, Nakamura T, Kitamura Y, Miwa T, Kameyama K, Hirose Y, Yoshida K
Oncotarget 2015;6(18):15871-15881
Oncotarget 2015;6(18):15871-15881
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas
Fishbein L, Khare S, Wubbenhorst B, DeSloover D, D’Andrea K, Merrill S, Cho N, Greenberg R, Else T, Montone K, LiVolsi V, Fraker D, Daber R, Cohen D, Nathanson K
Nature Communications 2015;6(1)
Nature Communications 2015;6(1)
Diffuse Midline Gliomas with Histone H3‐K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations
Solomon D, Wood M, Tihan T, Bollen A, Gupta N, Phillips J, Perry A
Brain Pathology 2015;26(5):569-580
Brain Pathology 2015;26(5):569-580
Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma
Oh J, Ohta T, Nonoguchi N, Satomi K, Capper D, Pierscianek D, Sure U, Vital A, Paulus W, Mittelbronn M, Antonelli M, Kleihues P, Giangaspero F, Ohgaki H
Brain Pathology 2015;26(4):517-522
Brain Pathology 2015;26(4):517-522
TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast
Yoshida M, Ogawa R, Yoshida H, Maeshima A, Kanai Y, Kinoshita T, Hiraoka N, Sekine S
British Journal of Cancer 2015;113(8):1244-1248
British Journal of Cancer 2015;113(8):1244-1248
Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma
Slatter T, Hsia H, Samaranayaka A, Sykes P, Clow W, Devenish C, Sutton T, Royds J, PC P, Cheung A, Hung N
The Journal of Pathology: Clinical Research 2015;1(2):95-105
The Journal of Pathology: Clinical Research 2015;1(2):95-105
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas
Cryan J, Haidar S, Ramkissoon L, Bi W, Knoff D, Schultz N, Abedalthagafi M, Brown L, Wen P, Reardon D, Dunn I, Folkerth R, Santagata S, Lindeman N, Ligon A, Beroukhim R, Hornick J, Alexander B, Ligon K, Ramkissoon S
Oncotarget 2014;5(18):8083-8092
Oncotarget 2014;5(18):8083-8092
Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas
Haberler C, Wöhrer A
Clinical Neuropathology 2014;33(03):108-111
Clinical Neuropathology 2014;33(03):108-111
Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDH
Cairncross J, Wang M, Jenkins R, Shaw E, Giannini C, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Huse J, Mehta M, Curran W
Journal of Clinical Oncology 2014;32(8):783-790
Journal of Clinical Oncology 2014;32(8):783-790
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells
Barszczyk M, Buczkowicz P, Castelo-Branco P, Mack S, Ramaswamy V, Mangerel J, Agnihotri S, Remke M, Golbourn B, Pajovic S, Elizabeth C, Yu M, Luu B, Morrison A, Adamski J, Nethery-Brokx K, Li X, Van Meter T, Dirks P, Rutka J, Taylor M, Tabori U, Hawkins C
Acta Neuropathologica 2014;128(6):863-877
Acta Neuropathologica 2014;128(6):863-877
The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas
Abedalthagafi M, Phillips J, Kim G, Mueller S, Haas-Kogen D, Marshall R, Croul S, Santi M, Cheng J, Zhou S, Sullivan L, Martinez-Lage M, Judkins A, Perry A
Modern Pathology 2013;26(11):1425-1432
Modern Pathology 2013;26(11):1425-1432
Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway
Scott H, Lovejoy C, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, De S, Petrini J, Sung P, Jasin M, Rosenbluh J, Zwang Y, Weir B, Hatton C, Ivanova E, Macconaill L, Hanna M, Hahn W, Lue N, Reddel R, Jiao Y, Kinzler K, Vogelstein B, Papadopoulos N, Meeker A
PLoS Genetics 2012;8(7):e1002772
PLoS Genetics 2012;8(7):e1002772
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber J, Korshunov A, Liu X, Jones D, Pfaff E, Jacob K, Sturm D, Fontebasso A, Quang D, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel J, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann M, Scheurlen W, Pekrun A, Frühwald M, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski P, Dong Z, Siegel P, Kulozik A, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins V, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister S, Jabado N
Nature 2012;482(7384):226-231
Nature 2012;482(7384):226-231
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao Y, Killela P, Reitman Z, Rasheed B, Heaphy C, de Wilde R, Rodriguez F, Rosemberg S, Oba-Shinjo S, Nagahashi Marie S, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman A, Riggins G, Holdhoff M, Burger P, McLendon R, Bigner D, Vogelstein B, Meeker A, Kinzler K, Papadopoulos N, Diaz L, Yan H
Oncotarget 2012;3(7):709-722
Oncotarget 2012;3(7):709-722
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors
de Wilde R, Heaphy C, Maitra A, Meeker A, Edil B, Wolfgang C, Ellison T, Schulick R, Molenaar I, Valk G, Vriens M, Borel Rinkes I, Offerhaus G, Hruban R, Matsukuma K
Modern Pathology 2012;25(7):1033-1039
Modern Pathology 2012;25(7):1033-1039
Molecular and Morphologic Correlates of the Alternative Lengthening of Telomeres Phenotype in High‐Grade Astrocytomas
Nguyen D, Heaphy C, de Wilde R, Orr B, Odia Y, Eberhart C, Meeker A, Rodriguez F
Brain Pathology 2012;23(3):237-243
Brain Pathology 2012;23(3):237-243
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Heaphy C, de Wilde R, Jiao Y, Klein A, Edil B, Shi C, Bettegowda C, Rodriguez F, Eberhart C, Hebbar S, Offerhaus G, McLendon R, Rasheed B, He Y, Yan H, Bigner D, Oba-Shinjo S, Marie S, Riggins G, Kinzler K, Vogelstein B, Hruban R, Maitra A, Papadopoulos N, Meeker A
Science 2011;333(6041):425-425
Science 2011;333(6041):425-425
No comments: Submit comment
Enhanced validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Genetic validation
- Main image
- Experimental details
- Western blot analysis in A-549 cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-ATRX antibody. Remaining relative intensity is presented. Loading control: Anti-GAPDH.
- Sample type
- Human
- Protocol
- Protocol
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Orthogonal validation
- Main image
- Experimental details
- Immunohistochemistry analysis in human cerebral cortex and liver tissues using HPA001906 antibody. Corresponding ATRX RNA-seq data are presented for the same tissues.
- Sample type
- Human
- Protocol
- Protocol
